1228585-88-3

Basic information

• Product Name: GS9620
• Synonyms: GS 9620;GS9620;GS-9620;4-Amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone;8-(3-(pyrrolidin-1-ylMethyl)benzyl)-4-aMino-2-butoxy-7,8-dihydropteridin-6(5H)-one;MFCD25372045 (GS-9620);4-Amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone GS 9620;GS9620, >=98%
• CAS NO: 1228585-88-3
• Molecular Formula: C₂₂H₃₀N₆O₂
• Molecular Weight: 410.5126
• Product Categories: API
• Mol File: 1228585-88-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.247±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (10 mg/ml)
• PKA: 10.34±0.20(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: GS9620(CAS DataBase Reference)
• NIST Chemistry Reference: GS9620(1228585-88-3)
• EPA Substance Registry System: GS9620(1228585-88-3)

Safety Data

• Hazardous Substances Data: 1228585-88-3(Hazardous Substances Data)

Usage

Description

GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic infection and transiently activated HIV expressionex vivoin latently-infected peripheral blood mononuclear cells (PBMCs) from virally suppressed patients. Currently, GS-9620 is under clinical evaluation for treating chronic HBV infection and for reducing latent reservoirs in virally-suppressed HIV-infected patients.

References

Lopatin, U, et al. "Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist." Antiviral Therapy18.3(2013):409-18. Gane, E. J., et al. "The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection." Journal of Hepatology63.2(2015):320. Lanford, Robert E., et al. "GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees." Gastroenterology 144.7(2013):1508.

Upstream product

• 1228588-13-3 ethyl 2-((6-amino-2-butoxy-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)acetate 
• 1228587-58-3 ethyl 2-(3-(pyrrolidin-1-ylmethyl)benzylamino)acetate 
• 91271-78-2 (3-(pyrrolidin-1-ylmethyl)phenyl)methanamine 
• 1228587-56-1 ethyl 2-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)acetate 
• 1228588-18-8 ethyl-Nα-[4-amino-2-methanesulfonyl-5-nitropyrimidin-6-yl],Nα-[3'-(pyrrolidin-1-ylmethyl)-benzyl]-glycinate 

Downstream Products

• 1454806-18-8 4-amino-2-n-butoxy-8-[3'-(pyrrolidin-1-ylmethyl)-benzyl]-5,6,7,8-tetrahydropteridin-6-one hydrochloride 
• 1228586-23-9 C₂₂H₃₀N₆O₃ 
• 1228586-24-0 C₂₂H₂₈N₆O₃ 

Relevant articles and documents

METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS

The present invention provides methods of preparing 4-amino-2-biitoxy-8-(3- (pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one and related compounds.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.